Review
Open access
Oct 2026
Real-World Implementation of Molecular Testing and Biomarker-Guided Therapies in HR+/HER2− Metastatic Breast Cancer
Background/Objectives: The introduction of biomarker-guided therapies, including PI3K, AKT and PARP inhibitors as well as Selective Estrogen Receptor Degraders (SERDs), has expanded treatment options and delayed the need for chemotherapy in hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negati...
C. Deutschmann, Matthias Filipovic, Dagmar Baha et al.
· Cancers · 0 citations